Skip to main content
Top
Published in: Internal and Emergency Medicine 7/2021

01-10-2021 | Heart Surgery | IM - ORIGINAL

Percutaneous pericardiocentesis for pericardial effusion: predictors of mortality and outcomes

Authors: Andrea Pennacchioni, Giulia Nanni, Fabio Alfredo Sgura, Jacopo Francesco Imberti, Daniel Enrique Monopoli, Rosario Rossi, Giuseppe Longo, Salvatore Arrotti, Marco Vitolo, Giuseppe Boriani

Published in: Internal and Emergency Medicine | Issue 7/2021

Login to get access

Abstract

Pericardial effusion can dangerously precipitate patient’s hemodynamic stability and requires prompt intervention in case of tamponade. We investigated potential predictors of in-hospital mortality, a composite outcome of in-hospital mortality, pericardiocentesis-related complications, and the need for emergency cardiac surgery and all-cause mortality in patients undergoing percutaneous pericardiocentesis. This is an observational, retrospective, single-center study on patients undergoing percutaneous pericardiocentesis (2010–2019). We enrolled 81 consecutive patients. Median age was 71.4 years (interquartile range [IQR] 58.1–78.1 years) and 51 (63%) were male. Most of the pericardiocentesis were performed in an urgency setting (76.5%) for cardiac tamponade (77.8%). The most common etiology was idiopathic (33.3%) followed by neoplastic (22.2%). In-hospital mortality was 14.8% while mortality during follow-up (mean 17.1 months) was 44.4%. Only hemodynamic instability (i.e., cardiogenic shock, hypotension refractory to fluid challenge therapy and inotropes) was associated with in-hospital mortality at the univariate analysis (odds ratio [OR] 7.2; 95% confidence interval [CI] 1.76–29.4). Non-neoplastic/non-idiopathic etiology and hemodynamic instability were associated with the composite outcome of in-hospital mortality, need for emergency cardiac surgery, or pericardiocentesis-related complications (OR 5.75, 95% CI 1.65–20.01, and OR 5.81, 95% CI 2.11–15.97, respectively). Multivariate Cox regression analysis adjusted for possible confounding variables (age, coronary artery disease, and hemodynamic instability) showed that neoplastic etiology was independently associated with medium-term mortality (hazard ratio [HR] 4.05, 95% CI 1.45–11.36). In a real-world population treated with pericardiocentesis for pericardial effusion, in-hospital adverse outcomes and medium-term mortality are consistent, in particular for patients presenting with hemodynamic instability or neoplastic pericardial effusion.
Literature
17.
go back to reference Adler Y, Charron P, Imazio M et al (2015) 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The task force for the diagnosis and management of pericardial diseases of the european society of cardiology (ESC) endorsed by: the european association for cardio-thoracic surgery (EACTS). Eur Heart J 36:2921–2964. https://doi.org/10.1093/eurheartj/ehv318CrossRefPubMed Adler Y, Charron P, Imazio M et al (2015) 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The task force for the diagnosis and management of pericardial diseases of the european society of cardiology (ESC) endorsed by: the european association for cardio-thoracic surgery (EACTS). Eur Heart J 36:2921–2964. https://​doi.​org/​10.​1093/​eurheartj/​ehv318CrossRefPubMed
Metadata
Title
Percutaneous pericardiocentesis for pericardial effusion: predictors of mortality and outcomes
Authors
Andrea Pennacchioni
Giulia Nanni
Fabio Alfredo Sgura
Jacopo Francesco Imberti
Daniel Enrique Monopoli
Rosario Rossi
Giuseppe Longo
Salvatore Arrotti
Marco Vitolo
Giuseppe Boriani
Publication date
01-10-2021
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine / Issue 7/2021
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-021-02642-x

Other articles of this Issue 7/2021

Internal and Emergency Medicine 7/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine